Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2005.368 | A Randomized, Single-Dose, Open-Label, Two-Way Crossover Study to Investigate the Pharmacokinetics of HPD-333-A Transdermal System in Healthy Subjects | Prof. Brian Tomlinson |
| 2005.379 | A Randomized, Single-Dose, Cross-Over, Bioavailability Study to Evaluate Propranolol HCI (DDC100105) Sublingual Tablet As Compared With Propranolol HCL (Inderal_) Immediate Release Oral Tablet in Healthy Volunteers | Prof. Chow SS Moses |
| 2013.081 | A Randomized, Single-blinded, Controlled Trial to Investigate the Efficacy of Low-Magnitude High-Frequency Vibration Treatment on Early Stage Osteoarthritic Knee (VTOAK) | Professor Leung Kwok Sui |
| 2006.117 | A Randomized, Single-blind, Parallel Group Pilot Study on the Use of NARL-Sonic Treatment to Induce Fat Mobilization and Visceral Fat Reduction | CHOW CC Francis |
| 2014.578 | A randomized, single-blind, controlled trial of electro-acupuncture for the treatment of symptomatic gallstone diseases | Dr. WONG Wendy |
| 2016.656 | A randomized, single blinded clinical trial on Stem cell therapy in osteochondral lesion associated with different hand and wrist pathology |
Dr. TSE Wing Lim 謝永廉 |
| 2011.568 | A Randomized, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients with Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC) | Dr Stephen Chan |
| 2009.565 | A randomized, placebo-controlled, double-blind trial of Phyllanthus urinaria (Hepaguard_) in adults with nonalcoholic steatohepatitis | Dr. Wong Wai Sun |
| 2006.202 | A Randomized, Placebo-Controlled, Double-Blind Phase II Study of Sequential Administration of Tarceva_ (Erlotinib) or Placebo in Combination with Gemcitabine/Platinum as First-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | Prof. Mok Tony |
| 2015.632 | A Randomized, Placebo Controlled Phase 3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1) |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2011.183 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Dr. TSANG Chiu Chi |
| 2011.182 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Dr. LUK Andrea On Yan |
| 2011.178 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Prof. YAN Bryan Ping Yen |
| 2011.175 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Prof. WONG Samuel Yeung Shan |
| 2011.152 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Dr. OZAKI Risa |
| 2012.225 | A Randomized, Phase III, Multicenter, Double Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MetMAb in Combination With Tarceva (Erlotinib) in Patients with Met Diagnostic-Positive Non-Small Cell Lung Cancer (NSCLC) who have Received Standard Chemotherapy for Advanced or Metastatic Disease | Prof. Mok Shu-Kam |
| 2008.286 | A Randomized, Parallel, Controlled Study to Evaluate the Role of Pretreatment Drug Susceptibility Tests in the Selection of Regimens of Chemotherapy for Retreatment of Relapsed Pulmonary TB in Guangzhou | Prof Hui David Shu Cheong |
| 2006.159 | A Randomized, Parallel Group, Placebo-Controlled, Double Blind Study to Assess the Safety and Tolerability of SB-681323 at 7.5mg Daily Dose for 28 days and its Effect on the Levels of Serum C-Reactive Protein (CRP) in Subjects with Rheumatoid Arthritis (RA) | Prof. Li Kwok Ming Edmund |
| 2005.095 | A Randomized, Open-labeled, Parallel, Comparative Study of the Efficacy and Tolerability of Rosuvastatin in LDL-C Reduction Using Different Dosing Regimes of 5mg Daily, 10mg Daily and 10mg Alternate day in Hong Kong Chinese Type 2 Diabetic Patients | Dr. Chow Chun Chung Francis |
| 2021.182 | A Randomized, Open-Label, Two-Arm Study to Evaluate the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2010.512 | A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of lamivudine and adefovir dipivoxil (100mg/10mg) to Heptodin_ (100mg) and Hepsera_ (10mg) | Professor Tomlinson Brian |
| 2023.069 | A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08) | Dr. LOONG Herbert Ho Fung |
| 2022.392 | A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non–Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations | Dr. LI Molly Siu Ching |
| 2023.102 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 | Prof. YEO Winnie Ming Ming |
| 2023.267 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy | Prof. YEO Winnie |
| 2024.409 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy | Prof. YEO Winnie |
| 2022.286 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 |
Prof. YEO Winnie 楊明明教授 |
| 2009.110 | A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Long-Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus | Dr. Ozaki Risa |
| 2009.121 | A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Long-Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus | Dr Tsang Chiu Chi |
| 2004.037 | A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase 3 Study of Oral ZD 1839(Iressa) versus Intravenous Docetaxel (Taxotere) in Patients with Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who have Previously Received Platinum Based Chemotherapy | Prof. Mok Tony |
| 2016.343 | A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer |
Dr. HO Wing Ming 何永明醫生 |
| 2021.521 | A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Subjects with Inadequate Response to C5 Inhibitor Therapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.517 | A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects with Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2021.539 | A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects with Chronic Hepatitis B Infection |
Dr. YIP Wai Man 葉偉文醫生 |
| 2019.584 | A randomized, open-label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1≥ 50% |
Prof. MOK Tony Shu Kam 莫樹錦教授 |
| 2013.269 | A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DIFFUSE LARGE B-CELL LYMPHOMA OR CD20+ FOLLICULAR NON-HODGKIN’S LYMPHOMA GRADES 1, 2 OR 3A | Dr. WONG Raymond Siu Ming |
| 2017.532 | A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with advanced Hepatocellular Carcinoma (HIMALAYA) |
Dr. CHAN Stephen 陳林醫生 |
| 2019.454 | A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib (Rivoceranib) Mesylate Versus Sorafenib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy |
Dr. CHAN Stephen Lam 陳林 |
| 2009.250 | A randomized, open-label, controlled, exploratory trial to characterize the results of daily oral administration of telbivudine 600mg and tenofovir disproxil fumarate 300mg in combination or telbivudine 600mg or tenofovir disproxil furmarate 300mg monothe | Professor Chan Henry Lik-Yuen |
| 2009.459 | A randomized, open-label, controlled, exploratory trial to characterize the results of daily oral administration of telbivudine 600 mg and tenofovir disoproxil fumarate 300 mg in combination or telbivudine 600 mg or tenofovir disoproxil fumarate 300 mg monotherapy given over 12 weeks on the kinetics of hepatitis B virus DNA in adults with HBeAg positive compensated CHB | Dr. Leung WY Nancy |
| 2009.458 | A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Adminstered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus | Dr. Chow Chun Chung Francis |
| 2007.090 | A Randomized, Open-Label Study in the Asia-Pacific Region Comparing the Safety and Efficacy of Etanercept with Usual DMARD Therapy in Subjects with Rheumatoid Arthritis | Prof. Li Edmund |
| 2006.461 | A Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab As First-Line Therapy in Subjects with Metastatic Colorectal Cancer | Prof. Ma BY Brigette |
| 2003.275 | A Randomized, Open-Label Phase 3 Study of Temozolomide Added to Whole Brain Radiation Therapy Versus Whole Brain Radiation Therapy Alone for the Treatment of Brain Metastases from Non-Small Cell Lung Cancer | Prof. Mok Tony |
| 2019.679 | A RANDOMIZED, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS |
Prof. LAU Alexander Yuk Lun 劉玉麟 |
| 2014.487 | A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042) | Prof. MOK Tony S. K. |
| 2013.483 | A randomized, open label, phase II study: stereotactic body radiotherapy (SBRT) vs conventional intensity-modulated radiotherapy (IMRT) for low or intermediate risk prostate cancer in Asia population | Dr. POON Ming Chun |
| 2018.036 | A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877)compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinumcontaining chemotherapy |
Dr. POON Darren Ming Chun 潘明駿醫生 |
| 2012.133 | A Randomized, Open Label, Multi-National Study of Cabazitaxel At 25 mg/m_ Every 3 Weeks in Combination With Prednisone Compared To Mitoxantrone in Combination With Prednisone in Asian Patients with Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen | Dr HO Wing-Ming |
| 2008.324 | A Randomized, Open Label, Multi-Center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients with Metastatic Clear Cell Carcinoma of the Kidney | Prof Ng Chi Fai |
Page 214 of 254.